COMMUNICATION

COM-2025-021

1 APRIL 2025

PLEASE REVIEW

Drug Information

PharmPix Clinical Department

PharmPix is committed to the health and wellness of our members.

The clinical team wants to communicate the latest up-to-date drug information requested.

Drug Information:

Remember that medical literature is dynamic and is continuously changing as new scientific knowledge is developed. We exhort the frequent revision of treatment guidelines to assure that your recommendations are consistent with the most updated information.

It is our priority to offer high-quality services and support practices for health promotion and diseases prevention. If you have any questions or wish to have more information regarding this document, you can call us directly or view PharmPix communications online.

QUESTIONS

Call us at 787-522-5252-ext.219

Access our recent communications at our providers' portal:

https://www.pharmpix.com/providers/

FDA Approves New Antibiotic for UTI

The Food and Drug Administration (FDA) has approved Blujepa (gepotidacin) for the treatment of female adult and pediatric patients aged 12 years and older weighing at least 40kg with uncomplicated urinary tract infections (uUTI) caused by the following susceptible microorganisms*: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus*, and *Enterococcus faecalis*.

uUTI: More Common than We Think

uUTIs are the most common infection among women, affecting around 16 million women in the United States annually. More than half of all women will experience a uUTI in their lifetime, with 30% having at least one recurrent infection.

The classic manifestations of uUTI consist of dysuria, urinary frequency, urinary urgency, and suprapubic pain.

What is Blujepa?

Blujepa is a first-in-class oral antibiotic with a novel mechanism of action. This is a triazaacenaphthylene antibiotic that inhibits bacterial DNA replication.

Its approval came from the phase 3 EAGLE-2 and EAGLE-3 trials, which showed that 58.5% of the patients treated with Blujepa saw symptom improvement, compared with 43.6% of those treated with nitrofurantoin.

Blujepa comes as a 750mg tablet. The recommended dosage is 1500mg (two 750mg tablets) taken orally twice daily for 5 days. Because of significant drug-drug interactions, patients taking CYP3A4 inhibitors, inducers, or substrates should not take Blujepa.

The most common adverse reactions are diarrhea, nausea, abdominal pain, flatulence, headache, soft feces, dizziness, vomiting, and vulvovaginal candidiasis.

Additional information can be found at: https://www.gsk.com/en-gb/media/press-releases/blujepa-gepotidacin-approved-by-us-fda-for-treatment-of-uncomplicated-urinary-tract-infections/

If you have any questions or wish to have more information regarding this document, you can call us at 787-522-5252-ext.219. Our pharmacists will help you. In addition, know that you can access our recent communications at our providers' portal: https://www.pharmpix.com/providers/.

pharmpix
POWERED BY ONEARK

REFERENCES:

1. GSK. (2025). Blujepa (gepotidacin) tablets, for oral use: Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218230s000lbl.pdf
2. Lutton, L. (2025, March 26). *FDA approves Uti Antibiotic, Blujepa*. Managed Healthcare Executive. https://www.managedhealthcareexecutive.com/view/fda-approves-uti-antibiotic-blujepa
3. Gupta, K. (nd). Acute simple cystitis in female adults. UpToDate. https://www.uptodate.com/contents/acute-simple-cystitis-in-female-adults?search=uncomplicated%20uti&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1#H899949262

urac ACCREDITED Pharmacy Benefit Management Expires 12/01/2025

2 Street 1, Suite 500
Guaynabo, PR 00968

Tel. 787.522.5252
Fax 866.912.2830

www.pharmpix.com
FRM-CL-000130-001

CLINICAL PEARLS BY PHARMPIX